Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis

Journal of Periodontology

Volumn 82, Issue 1, 2011, Pages 96-105

  Flemmig, Thomas F ^a   Petersilka, Gregor ^a,b   Völp, Andreas ^c   Gravemeier, Martina ^a   Zilly, Martin ^b   Mross, Daniela ^a   Prior, Karola ^a   Yamamoto, Julie ^a   Beikleri, Thomas ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Psy Consult Scientific Services ^*

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anti bacterial agents; Biofilms; Dental scaling; Moxifloxacin; Periodontal diseases; Periodontitis

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; PLACEBO; QUINOLINE DERIVATIVE;

ADULT; AGED; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTEROIDES; CHRONIC PERIODONTITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GINGIVA BLEEDING; GINGIVA DISEASE; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; PERIODONTAL DISEASE; PERIODONTAL POCKET; PHASE 2 CLINICAL TRIAL; PORPHYROMONAS GINGIVALIS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; SAFETY; STREPTOCOCCUS INTERMEDIUS; TOOTH PLAQUE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TREPONEMA DENTICOLA;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIAL LOAD; BACTEROIDES; CHRONIC PERIODONTITIS; DENTAL PLAQUE; DENTAL SCALING; DRUG RESISTANCE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; GINGIVAL HEMORRHAGE; GINGIVAL RECESSION; HUMANS; MALE; MIDDLE AGED; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL POCKET; PLACEBOS; PORPHYROMONAS GINGIVALIS; QUINOLINES; ROOT PLANING; SAFETY; STREPTOCOCCUS INTERMEDIUS; TREATMENT OUTCOME; TREPONEMA DENTICOLA;

EID: 79251610898     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2010.100124     Document Type: Article

References (43)

1. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003;22:203-221.
2. Tomás I, Tomás M, Alvarez M, et al. Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials. Oral Microbiol Immunol 2007;22:298-303.
3. Moxifloxacin. [No authors listed] Tuberculosis (Edinb) 2008;88:127-131.
4. Culley CM, Lacy MK, Klutman N, Edwards B. Moxifloxacin: Clinical efficacy and safety. Am J Health Syst Pharm 2001;58:379-388.
5. Balfour JA, Lamb HM. Moxifloxacin: A review of its clinical potential in the management of communityacquired respiratory tract infections. Drugs 2000;59:115-139.
6. Al-Nawas B, Walter C, Morbach T, et al. Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: A pilot study. Eur J Clin Microbiol Infect Dis 2009;28:75-82.
7. Ang JY, Asmar BI. Multidrug-resistant viridans streptococcus (MDRVS) osteomyelitis of the mandible successfully treated with moxifloxacin. South Med J 2008;101:539-540.
8. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactamand amoxicillinclavulanate for the treatment of complicated intraabdominal infections. Ann Surg 2006;244:204-211.
9. Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: A randomized clinical trial. Ophthalmology 2007;114:1622-1629.
10. Mah FS. Fourth-generation fluoroquinolones: New topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 2004;15:316-320.
11. O'Brien TP. Evidence-based review of moxifloxacin. Int Ophthalmol Clin 2006;46:61-72.
12. He L, Ta CN, Hu N, Sinnar S, Mino de Kaspar H. Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria. J Ocul Pharmacol Ther 2009;25:373-378.
13. Milazzo I, Blandino G, Musumeci R, Nicoletti G, Lo Bue AM, Speciale A. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections. Int J Antimicrob Agents 2002;20:451-456.
14. Müller HP, Holderrieth S, Burkhardt U, Höffler U. In vitro antimicrobial susceptibility of oral strains of Actinobacillus actinomycetemcomitans to seven antibiotics. J Clin Periodontol 2002;29:736-742.
15. Eick S, Seltmann T, Pfister W. Efficacy of antibiotics to strains of periodontopathogenic bacteria within a single species biofilm: An in vitro study. J Clin Periodontol 2004;31:376-383.
16. Eick S, Pfister W. Efficacy of antibiotics against periodontopathogenic bacteria within epithelial cells: An in vitro study. J Periodontol 2004;75:1327-1334.
17. Guentsch A, Jentsch H, Pfister W, Hoffmann T, Eick S. Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis. J Periodontol 2008;79:1894-1903.
18. Moher D, Schulz KF, Altman DG; CONSORT GROUP (Consolidated Standards of Reporting Trials). The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-662.
19. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
20. Quirynen M, Mongardini C, de Soete M, et al. The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult periodontitis. Long-term clinical and microbiological observations. J Clin Periodontol 2000;27:578-589.
21. O'Leary TJ, Drake RB, Naylor JE. The plaque control record. J Periodontol 1972;43:38-40.
22. Ashimoto A, Chen C, Bakker I, Slots J. Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol 1996;11:266-273.
23. Bodinka A, Schmidt H, Henkel B, Flemmig TF, Klaiber B, Karch H. Polymerase chain reaction for the identification of Porphyromonas gingivalis collagenase genes. Oral Microbiol Immunol 1994;9:161-165.
24. Slots J, Ashimoto A, Flynn MJ, Li G, Chen C. Detection of putative periodontal pathogens in subgingival specimens by 16S ribosomal DNA amplification with the polymerase chain reaction. Clin Infect Dis 1995;20(Suppl. 2):S304-S307.
25. Tønjum T, Haas R. Identification of Actinobacillus actinomycetemcomitans by leukotoxin gene-specific hybridization and polymerase chain reaction assays. J Clin Microbiol 1993;31:1856-1859.
26. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339:237-238.
27. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
28. Maurer W, Hothorn L, Lehmacher W. Multiple comparisons in drug clinical trials and pre-clinical assays: A priori ordered hypotheses. In: Vollmar J, ed. Principles of Testing in Clinical and Pre-clinical Trials Biostatistics in the Chemical-Pharmaceutical Industry (in German). Stuttgart: Gustav-Fischer Verlag; 1995:3-18.
29. Kieser M, Bauer P, Lehmacher W. Inference on multiple endpoints in clinical trials with adaptive interim analyses. Biom J 1999;41:261-277.
30. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582.
31. Eick S, Schmitt A, Sachse S, Schmidt KH, Pfister W. In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains. J Antimicrob Chemother 2004;54:553-556.
32. Bonito AJ, Lux L, Lohr KN. Impact of local adjuncts to scaling and root planing in periodontal disease therapy: A systematic review. J Periodontol 2005;76:1227-1236.
33. Hanes PJ, Purvis JP. Local anti-infective therapy: Pharmacological agents. A systematic review. Ann Periodontol 2003;8:79-98.
34. Ah MK, Johnson GK, Kaldahl WB, Patil KD, Kalkwarf KL. The effect of smoking on the response to periodontal therapy. J Clin Periodontol 1994;21:91-97.
35. Kaldahl WB, Johnson GK, Patil KD, Kalkwarf KL. Levels of cigarette consumption and response to periodontal therapy. J Periodontol 1996;67:675-681.
36. Kinane DF, Radvar M. A six-month comparison of three periodontal local antimicrobial therapies in persistent periodontal pockets. J Periodontol 1999;70:1-7.
37. Mombelli A, Lehmann B, Tonetti M, Lang NP. Clinical response to local delivery of tetracycline in relation to overall and local periodontal conditions. J Clin Periodontol 1997;24:470-477.
38. Ryder MI, Pons B, Adams D, et al. Effects of smoking on local delivery of controlled-release doxycycline as compared to scaling and root planing. J Clin Periodontol 1999;26:683-691.
39. Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: A controlled trial. J Periodontol 2001;72:1535-1544.
40. Machion L, Andia DC, Benatti BB, et al. Locally delivered doxycycline as an adjunctive therapy to scaling and root planing in the treatment of smokers: A clinical study. J Periodontol 2004;75:464-469.
41. Zinner SH, Lubenko IY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: Related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003;52:616-622.
42. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:1604-1613.
43. Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004;24:161-167.